Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Bayer submits marketing authorization application for BAY-94-9027 in Japan

Oct. 18, 2017

FDA accepts ProMetic's BLA for Ryplazim

Oct. 16, 2017

EMA accepts Cinfa's MAA for biosimilar pegfilgrastim B-12019

Oct. 6, 2017

FDA accepts IND for gene-edited cell therapy for beta-thalassemia

Oct. 5, 2017

FDA not to hold committee meeting to discuss Rigel's NDA for fostamatinib

Oct. 3, 2017

Ablynx reports phase III results for caplacizumab in aTTP

Oct. 2, 2017

Ruconest provides clinically meaningful relief of symptons in phase II study

Oct. 2, 2017

Alnylam Pharmaceuticals begins phase II study of cemdisiran in aHUS

Sep. 28, 2017

Topline results reported from Japanese phase II study of vadadustat in NDD-CKD

Sep. 27, 2017

Catalyst Biosciences' CB-2679d awarded FDA orphan drug status for hemophilia B

Sep. 27, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis
BioWorld Science
More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...